Meeting
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
Authors
Eric Baudin
Institut Gustave Roussy, Villejuif, France
Eric Baudin , Camilo Jimenez , Martin Fassnacht , Salvatore Grisanti , Catharina Wilhelmina Menke , Harm Haak , Vivek Subbiah , Jaume Capdevila , Christelle De La Fouchardiere , Dan Granberg , Gedske Daugaard , Otilia Kimpel , Matthias Kroiss , Livia Lamartina , Laurent Chêne , Jean-Michel Paillarse , Alfredo Berruti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Other GU Kidney and Bladder Cancer
Clinical Trial Registration Number
NCT04187404
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4596)
DOI
10.1200/JCO.2022.40.16_suppl.4596
Abstract #
4596
Poster Bd #
87
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
First Author: Wolfgang Wick
Poster
2023 ASCO Annual Meeting
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
First Author: Wolfgang Wick
Poster
2022 ASCO Annual Meeting
A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).
First Author: Pier Luigi Zinzani
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Immunologic efficacy of E39 & E39' vaccination in a phase I/IIa trial in ovarian and endometrial cancer patients.
First Author: Tommy A Brown